Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Non-Current Assets (2022 - 2025)

BioXcel Therapeutics has reported Non-Current Assets over the past 4 years, most recently at $231000.0 for Q4 2025.

  • Quarterly results put Non-Current Assets at $231000.0 for Q4 2025, down 75.53% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 58.44% YoY), and the annual figure for FY2025 was $231000.0, down 75.53%.
  • Non-Current Assets for Q4 2025 was $231000.0 at BioXcel Therapeutics, down from $389000.0 in the prior quarter.
  • Over the last five years, Non-Current Assets for BTAI hit a ceiling of $3.5 million in Q1 2022 and a floor of $231000.0 in Q4 2025.
  • Median Non-Current Assets over the past 4 years was $1.5 million (2023), compared with a mean of $1.7 million.
  • Biggest five-year swings in Non-Current Assets: fell 18.6% in 2023 and later plummeted 75.53% in 2025.
  • BioXcel Therapeutics' Non-Current Assets stood at $3.0 million in 2022, then crashed by 47.77% to $1.6 million in 2023, then plummeted by 39.45% to $944000.0 in 2024, then plummeted by 75.53% to $231000.0 in 2025.
  • The last three reported values for Non-Current Assets were $231000.0 (Q4 2025), $389000.0 (Q3 2025), and $546000.0 (Q2 2025) per Business Quant data.